Peptide Tools to Study SARS-CoV-2

About SARS-CoV-2

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of coronavirus disease 2019 (Covid-19), is responsible for the 2020 global pandemic. Developing vaccines and therapies that are safe, effective, and rapidly deployable is an urgent global health priority.

JPT's Peptide Tools to Study SARS-CoV2

The global research and development efforts as well as initiation of clinicial trials evaluating vaccines and drugs generated an urgent demand for SARS-CoV-2 related peptide products enabling definition of immune-relevant antigens, identification of B- and T-cell epitopes, development of immune-therapeutic &diagnotic strategies and clinical trial immune monitoring.
In response, JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools to study both humoral and cellular immunity and to support clinicial vaccination trials. Applications for our ready-to-use & customized peptide formats include:

  • SARS-CoV-2 Clinical Trial Immune Monitoring
  • SARS-CoV-2 Correlation of Cellular and Humoral Immune Responses
  • SARS-CoV-2 Evaluation of Cross Reactivities
  • SARS-CoV-2 Vaccine Target Identification
  • SARS-CoV-2 Blood and Sero Test Development
  • SARS-CoV-2 T-and B-cell Epitope Discovery

Cellular Immunity

Please visit the respective product page for detailed information and pricing.

PepMix™ Peptide Pools for

  • Antigen-specific T-cell stimulation
  • Cellular immune monitoring
  • Vaccine target discovery
  • Blood test development
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Cell therapy development

> SARS-CoV-2 PepMixes™ Product Page
> Customized PepMix Pools Product Page
> Clinical grade customized PepMix™ Pools Product Page
> Control Pools Product Page

Epitope Mapping Peptide Sets (EMPS)

  • Efficient epitope mapping and identification
  • Matrix Pools and individual peptides spanning a whole antigen in one set
  • Minimal sample amount required

> Product Page

Antigen Peptides for

  • Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
  • Immune monitoring
  • Proliferation assays
  • T-cell expansion

> Product Page

Humoral Immunity

Please visit the respective product page for detailed information and pricing.

RepliTope™ Pan Coronavirus for

  • Humoral immune monitoring
  • Antibody epitope discovery
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Seromarker discovery

> RepliTope™ Pan Coronavirus Product Page
Customized PepStar™ Peptide Microarrays Product Page

Multiwell RepliTopes™ SARS-CoV-2

  • Immune monitoring
  • Antibody epitope discovery
  • Screening individual antigens of SARS-CoV-2 and SARS
  • Seromarker discovery

> RepliTope™ Multiwell Microarrays

Three-Step Antibody Response Profiling Service

  • High content, peptide resolved antibody response profiling using thousands of tailored peptides covering the entire SARS CoV-2 genome using smallest sample volumes
  • Study of antibody cross reactivities between SARS CoV-2 and other corona viruses (HCoVs)
  • Verification of the peptide binders using multiwell our array format with large numbers of samples
  • Transfer of results to ELISA platform for rapid test development

> Three-Step Antibody Response Profiling Service

Peptide ELISA

  • Peptide ELISA development and service using your SARS CoV-2 peptides alone or in combination other corona virus (HCoV) peptides
  • ELISA based validation service of peptide binders identified using JPT’s peptide microarray platforms
  • Collaborative ELISA test development

> Peptide ELISA

Clinical Trial Immune Monitoring & Cell Therapy

Please visit the respective product page for detailed information and pricing.

Clinical Grade Peptides & PepMix™ Peptide Pools

  • High quality chemically synthesized antigen source for vaccine trial monitoring
  • Ancillary reagents for cellular therapy development
  • Full analytical coverage, stability testing, batch documentation and more

> Clinical Peptides & PepMix Peptide Pools™ Product Page


Please visit the respective product page for detailed information and pricing.

SpikeMix™ SARS-CoV-2 for

  • Identify SARS CoV-2 antigens from biological samples
  • Mass spectrometry based assays (MRM)
  • Screen 23 proteotypic peptides from SARS-CoV-2

> SpikeMix™ SARS-CoV-2 product page

References with SARS-CoV-2 Peptide Tools

Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)

More references



Check our list of products,
click and go.

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!